Browse drugs

…by cemiplimab 350 mg IV on Day 5, or single-agent chemotherapy (vinorelbine, gemcitabine, or docetaxel). The primary endpoint is overall su…

…ing success and improve final product characteristics. Notably, IMA203 manufacturing achieved a 95% success rate at the RP2D (1-10x10 …

… 3.0 cm in longest dimension. Escalating dose concentrations of PH-762 (from 1.14 mg/mL through 22.00 mg/mL) are tested serially in co…

…sions These findings provide a rationale for the combination of STAR0602 and SOC therapy in the clinical setting for patients with recur…

…usted CD8+ T cells and enhanced anti-tumor immunity.Conclusions ABT-863 is a first-in-class CCR8 inverse agonist antibody that promotes…

…d and neck squamous cell carcinoma (HNSCC), IMANs combined with nivolumab induced greater tumor cytotoxicity than CPI alone. Notably, IMA…

…ly relapsed and refractory AML. Am J Hematol 2024:99(5):890-899.Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, C…

…expressing human IL-21(HSV C021) in combination with ROR1.CAR.5 NKTR-255 is an investigational IL-15Rα-dependent, polymer-conjugated IL-…

…nti-tumour immunity and the benefit of combination therapy with IL-15 to enhance ICI responsiveness and anti-tumour activity.Methods …

… secondary assessments of engraftment and preliminary efficacy. KAN-001 will be administered orally in an encapsulated frozen liquid fo…

…lator of anti-tumor immunity. Critically, the combination of RT+FASNi+anti-PD-1 induces durable tumor rejection and immunological mem…

…mab and chemotherapy. These findings highlight the potential of STK-012 to overcome key limitations of the next wave immunotherapies by…